Eli Lilly and Co (BSP:LILY34)
R$ 168.31 -2.98 (-1.74%) Market Cap: 4.63 Til Enterprise Value: 4.77 Til PE Ratio: 113.74 PB Ratio: 61.32 GF Score: 73/100

Eli Lilly and Co to Discuss ESMO 2020 Presentations - Conference Call Transcript

Sep 21, 2020 / 07:00PM GMT
Release Date Price: R$26.88 (-2.13%)

Sep 21, 2020 / 07:00PM GMT
Presentations - Conference Call
Sep 21, 2020 / 07:00PM GMT

=====================
Corporate Participants
=====================
* Anne E. White
Eli Lilly and Company - Senior VP & President of Lilly Oncology
* Daniel M. Skovronsky
Eli Lilly and Company - Senior VP, Chief Scientific Officer & President of Lilly Research Labs
* Jacob S. Van Naarden
Loxo Oncology, Inc. - COO
* Martin Frenzel
Eli Lilly and Company - Principal Research Scientist of Oncology
* Maura Dickler
Eli Lilly and Company - VP of Oncology Late-Stage Development
* Mike Czapar
Eli Lilly and Company - Director of IR

=====================
Conference Call Participants
=====================
* Carter Lewis Gould
Barclays Bank PLC, Research Division - Senior Analyst
* Christopher Thomas Schott
JPMorgan Chase & Co, Research Division - Senior Analyst
* Geoffrey Christopher Meacham
BofA Merrill Lynch, Research Division - Research Analyst
* Jonathan Lim
UBS

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot